Evidence map›Paper›PMID 29330417›Full record

ArticleScientific reports2018

High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia.

Elisabeth M P Steeghs, Marjolein Bakker, Alex Q Hoogkamer, Judith M Boer, Quirine J Hartman, Femke Stalpers, Gabriele Escherich, Valerie de Haas, Hester A de Groot-Kruseman, Rob Pieters and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Diagnostic and prognostic value ofFrontiers in immunology · 2022
    Article
  5. Article
  6. Taking One Step Back in Familial Hypercholesterolemia:Arteriosclerosis, thrombosis, and vascular biology · 2020
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Elisabeth M P SteeghsDepartment of Pediatric Oncology/Hematology, Erasmus Medical Center - Sophia Children's Hospital, Rotterdam, The Netherlands.
Marjolein BakkerDepartment of Pediatric Oncology/Hematology, Erasmus Medical Center - Sophia Children's Hospital, Rotterdam, The Netherlands.
Alex Q HoogkamerDepartment of Pediatric Oncology/Hematology, Erasmus Medical Center - Sophia Children's Hospital, Rotterdam, The Netherlands.
Judith M BoerDepartment of Pediatric Oncology/Hematology, Erasmus Medical Center - Sophia Children's Hospital, Rotterdam, The Netherlands.
Quirine J HartmanDepartment of Pediatric Oncology/Hematology, Erasmus Medical Center - Sophia Children's Hospital, Rotterdam, The Netherlands.
Femke StalpersDepartment of Pediatric Oncology/Hematology, Erasmus Medical Center - Sophia Children's Hospital, Rotterdam, The Netherlands.
Gabriele EscherichCOALL - German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia, University Medical Centre Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Valerie de HaasDCOG, Dutch Childhood Oncology Group, The Hague, The Netherlands.
Hester A de Groot-KrusemanDCOG, Dutch Childhood Oncology Group, The Hague, The Netherlands.
Rob PietersPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Monique L den BoerDepartment of Pediatric Oncology/Hematology, Erasmus Medical Center - Sophia Children's Hospital, Rotterdam, The Netherlands. m.l.denboer@erasmusmc.nl.
Erasmus MC - Sophia Children’s Hospital · NLPrincess Máxima Center · NLStichting Kinderoncologie Nederland · NLUniversity Medical Center Hamburg-Eppendorf · DE

Funding

CPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2015 to 2019
$15.1M
NIGMS NIH HHS P50 GM115279
6 · The paper itself

Abstract

Approximately 25% of the pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cases are genetically unclassified. More thorough elucidation of the pathobiology of these genetically unclassified ('B-other') cases may identify novel treatment options. We analyzed gene expression profiles of 572 pediatric BCP-ALL cases, representing all major ALL subtypes. High expression of STAP1, an adaptor protein downstream of the B-cell receptor (BCR), was identified in BCR-ABL1-like and non-BCR-ABL1-like B-other cases. Limma analysis revealed an association between high expression of STAP1 and BCR signaling genes. However, STAP1 expression and pre-BCR signaling were not causally related: cytoplasmic Igμ levels were not abnormal in cases with high levels of STAP1 and stimulation of pre-BCR signaling did not induce STAP1 expression. To elucidate the role of STAP1 in BCP-ALL survival, expression was silenced in two human BCP-ALL cell lines. Knockdown of STAP1 did not reduce the proliferation rate or viability of these cells, suggesting that STAP1 is not a likely candidate for precision medicines. Moreover, high expression of STAP1 was not predictive for an unfavorable prognosis of BCR-ABL1-like and non-BCR-ABL1-like B-other cases. Remarkably, DUX4-rearrangements and intragenic ERG deletions, were enriched in cases harboring high expression of STAP1.

Indexed as

Adaptor Proteins, Signal TransducingAntineoplastic AgentsCell Line, TumorCell ProliferationCell SurvivalChromosome AberrationsFusion Proteins, bcr-ablHomeodomain ProteinsHumansPolymorphism, Single NucleotidePrecursor B-Cell Lymphoblastic Leukemia-LymphomaReceptors, Antigen, B-CellRNA InterferenceRNA, Small InterferingSignal TransductionTranscriptional Regulator ERGAdaptor Proteins, Signal TransducingAntineoplastic AgentsDUX4L1 protein, humanERG protein, humanFusion Proteins, bcr-ablHomeodomain ProteinsReceptors, Antigen, B-CellRNA, Small InterferingSTAP1 protein, humanTranscriptional Regulator ERG

Identifiers

PMID29330417
PMCPMC5766593
OpenAlexW2782690747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.